Breast Cancer Coverage from Every Angle

Sibylle Loibl, MD, PhD, on Adding Durvalumab to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Posted: Wednesday, July 7, 2021

Sibylle Loibl, MD, PhD, of the German Breast Group, discusses the clinical implications of adding durvalumab to neoadjuvant anthracycline therapy for women with triple-negative breast cancer, the rationale for this regimen as well as its toxicities, and next steps in the treatment’s evolution.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.